ALSO NOTED: Sucampo Pharma names new CEO; Genetic tests are going DTC at a fast pace; Panel: Give FDA power to recall; and much

> Teva and the Technion Israel Institute of Technology are exploring a pact to develop stem cell lines for research work. Report

> Chutes & Ladders: Sucampo Pharma has named Kunihiko Soneoka as representative director, president and CEO. Release

> Predictive gene-based tests are going DTC, and a number of experts worry that it's all happening way too fast. Article

> A presidential panel is set to recommend giving the agency the authority to recall products all by its lonesome. Report

> The northward migration of drug buyers is slackening, according to pharmaceuticals datameister IMS Health. In 2006 U.S. customers only spent $211 on meds from Canadian pharmacies, compared with $420 million in 2005. Report

> Better late than never, Bristol-Myers Squibb might say. In a move that's sure to incite debate, the FDA says it will allow BMS to market its schizophrenia med Abilify for use in adolescents. Report

> Can poor countries get the meds they need for their people only by circumventing patents? That's the debate this week at a WHO confab aimed at supplying the developing world with the drugs it needs. Report

> A report in the Journal of Clinical Investigation sheds new light on the role of WNK kinases in regulating blood pressure, which in likely to trigger research into new therapies for the very common, lethal disease. Report

> What do Tokyo teenagers falling from buildings have in common with Roche? Possibly Tamiflu. Report

And Finally… A novel vaccine developed at The Scripps Research Institute at La Jolla may offer a new way to block infections without sparking bacterial resistance. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.